Account
Articles
23.07.2014
New tax proposed to manage healthcare expenditure

If spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed

Read more
News
07.07.2014
Incl. Is 2015 a turning point for bio similar

Including Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...

Read more
News
20.05.2014
The latest in pharma pricing and market access

Our quarterly newsletter shares our perspectives on the latest news, developments and thinking withi...

Read more
Articles
15.05.2014
Impact of value and price on market access

How different perspectives on value and price can impact market access

Read more
Articles
13.05.2014
New Hepatitis drug cost

Attack on Sovaldi's controversial $84000 price tag by lawmakers

Read more
Articles
29.03.2014
New implications for HTA in France

The purpose of the new HTA is to ensure proportional incremental costs and effectiveness, as well as...

Read more
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch